3种用药方案治疗冠心病心绞痛的最小成本分析

目的:评价3种给药方案治疗冠心病心绞痛的经济学效果。方法:按不同治疗方案分为硝酸甘油注射液(A组,n=30)、单硝酸异山梨酯注射液(B组,n=30)、参芎注射液(C组,n=30)3组,疗程均为14d。考察3组疗效及不良反应,并进行药物经济学分析。结果:A、B、C组总有效率分别为83.3%、76.7%、66.7%,差异无统计学意义;A、B、C组不良反应发生率分别为43.3%、23.3%、0.0%,差异有统计学意义(P<0.001);A、B、C组总成本分别为(119.67±3.75)、(329.15±9.53)、(1109.90±254.07)元,差异有统计学意义(P<0.01)。结论:A组与B组不良反应发生率较高,但这些反应均不严重,且输液结束后即可消失,权衡利弊仍选A组为最佳方案,B组其次,C组最差。

Cost - Minimization Analysis of 3 Therapeutic Regimens for Angina Pectoris in Patients with Coronary Heart Disease

OBJECTIVE： To evaluate the economic efficacy of 3 therapeutic regimens in the treatment of angina pectoris of patients with coronary artery disease（CAD）. METHODS： The patients were assigned to receive nitroglycerin injection （Group A, n = 30）, isosorbide mononitrate injection（Group B, n = 30） or shenxiong injection（Group C, n = 30） for 14 days. The clinical efficacy and adverse drug reactions（ADR） in the 3 groups were observed and the pharmacoeconomic analysis was carried out. RESULTS： The total effective rates of A, B and C groups were 83.3%, 76.7% and 66.7%, respectively, showing no significant difference among the 3 groups; the incidences of ADR of A, B and C groups were 43.3%, 23.3% and 0.0%, respectively, manifesting sharp significant difference（P〈0.001） ; the total costs were（ 119.67 ± 3.75） yuan, （329.15± 9.53） yuan and （ 1 109.90±254.07） yuan, respectively, presenting significant differences among the 3 groups（ P 〈 0.01）. CONCLUSION ： The incidences of ADR of groups A and B were higher but mild, which disappeared after completion of drug infusion. Considering the merits and demerits, Group A is regarded as the optimal one, followed by Group B, and Group C is the worst one.